Scribe Therapeutics
Brief Description
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
Inventor
Jennifer Doudna
Tech Category
- Research Tools
- Medical Therapeutics
In the News
- Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal 9/27/22
- Scribe Therapeutics Expands Collaboration With Biogen to Second Target 5/2/22
- Scribe Therapeutics Wins 2021 Pantheon Rising Star Award 11/4/21
- Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing 3/31/21
- CRISPR-Based ALS Treatment Being Developed by Scribe and Biogen 10/8/20
© 2022 Regents of the University of California. All Rights Reserved.